CD81 and breast carcinoma: We developed and validated a platform based on nanowell arrays for directly profiling EV secretion from single cells and used these to establish cells derived from a clinically relevant mouse breast cancer model that have significant differences in the rate of secretion of CD81+CD63+EVs.